AMGN vs. LLY: Amgen vs. Eli Lilly Stock Comparison

Company Profile

Amgen (AMGN) and Eli Lilly (LLY) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but AMGN is classified in Biotechnology while LLY is classified in Pharmaceuticals.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both Amgen (AMGN) at 78.35% and Eli Lilly (LLY) at 86.02% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

Both Amgen (AMGN) at 24.14% and Eli Lilly (LLY) at 31.90% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.

Both Amgen (AMGN) at 35.79% and Eli Lilly (LLY) at 53.66% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both Amgen (AMGN) at 9.95% and Eli Lilly (LLY) at 44.70% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Both Amgen (AMGN) at 88.23% and Eli Lilly (LLY) at 95.99% sit in the top peer quartile for EPS growth, so each is compounding per-share earnings faster than typical industry peers.

Growth Metrics

Financial Strength

Both Amgen (AMGN) at 1.48 and Eli Lilly (LLY) at 1.39 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Both balance sheets lean debt-heavy versus peers, but AMGN is more stretched: Eli Lilly (LLY) at 1.23 sits in the higher-leverage quartile and Amgen (AMGN) at 3.76 is above its industry benchmark range.

Financial Strength Metrics

Dividends

Both Amgen (AMGN) at 2.16% and Eli Lilly (LLY) at 0.49% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

Both Amgen (AMGN) at 57.62% and Eli Lilly (LLY) at 21.71% pay out more of their earnings than any of their industry peers — the thinnest cover in their groups, so dividend headroom deserves attention.

Dividend Metrics

Valuation

Amgen (AMGN) at 26.69 is near its industry’s usual P/E ratio, while Eli Lilly (LLY) at 43.95 sits in the richer quartile — LLY needs stronger growth or earnings quality to justify the premium.

On P/S ratio, both Amgen (AMGN) at 6.40 and Eli Lilly (LLY) at 13.95 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

Measured against book value, both Amgen (AMGN) at 17.35 and Eli Lilly (LLY) at 29.96 look expensive — each P/B ratio sits above its industry’s benchmark range.

Valuation Metrics